April 11, 2017 / 9:02 PM / 3 months ago

BRIEF-Neurocrine announces FDA approval of Ingrezza TM (valbenazine) capsules

1 Min Read

April 11 (Reuters) - Neurocrine Biosciences Inc:

* Neurocrine announces FDA approval of Ingrezza TM (valbenazine) capsules as the first and only approved treatment for adults with tardive dyskinesia (TD)

* Neurocrine Biosciences Inc- "Ingrezza will be in distribution channel next week and will be available through a select pharmacy network" Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below